Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
But more detail is awaited, especially on toxicity.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
